查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993054

肺气肿治疗市场：2026-2032年全球市场预测（依治疗方法、药物类别、治疗线、给药途径、剂型、产品类型及分销管道划分）

Emphysema Treatment Market by Treatment Type, Drug Class, Therapy Line, Route Of Administration, Dosage Form, Product Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肺气肿治疗市场价值将达到 73.2 亿美元，到 2026 年将成长至 78.4 亿美元，到 2032 年将达到 119.4 亿美元，复合年增长率为 7.23%。

主要市场统计数据
基准年 2025 73.2亿美元
预计年份：2026年 78.4亿美元
预测年份 2032 119.4亿美元
复合年增长率 (%) 7.23%

全面介绍不断变化的肺气肿治疗格局、临床重点以及影响治疗决策的新挑战。

由于肺气肿具有进行性发展、症状负担重和医疗资源消耗高等特点，因此在慢性呼吸系统疾病的治疗中，它仍然是临床和商业性领域的重点领域。肺气肿的整体情况包括药物治疗和手术治疗，两者各有不同的临床目标。药物治疗旨在抑制发炎、缓解气流阻塞和减少急性加重，而手术治疗则仅限于经过严格筛选、旨在改善肺功能和生活品质的患者。本导言概述了许多正在重塑患者照护、创新研发管线和支付方格局的因素。

药物治疗、器械管理和手术方面的创新如何重塑肺气肿治疗路径和相关人员的期望。

肺气肿治疗的现状正经历着一场变革，其驱动力来自药物治疗的创新、外科技术的改进以及对综合护理模式日益增长的重视。新型联合治疗和器械平台正在拓展临床选择，而微创手术和瓣膜治疗则为过去选择有限的患者提供了新的希望。这些变化并非孤立发生，而是与监管决策、报销途径和临床指南的更新相互作用，从而加速了特定干预措施的推广应用。

2025 年美国关税重组对肺气肿治疗供应链、采购韧性和临床连续性的营运和策略影响。

2025年美国关税和贸易政策变化所带来的累积影响，为医疗器材製造商和经销商创造了一个必须谨慎应对的商业环境。关税表的变化影响了专用吸入器、某些生物製药成分以及用于高级肺部手术的外科器械的进口成本。为此，製造商加快了对其供应链的重新评估、采购合约的重新谈判以及关键零件的在地采购，以降低贸易相关的成本波动风险。

多方面的细分洞察揭示了治疗类型、药物类别、治疗线和供应途径如何决定临床应用和商业性定位。

关键的市场区隔洞察揭示了不同治疗方法类型、药物分类、治疗线、给药途径、剂型、分销管道和产品类型在治疗方法选择和商业性策略上的差异。根据治疗类型，市场可区分正在研究的药物治疗方案（例如抗生素、支气管扩张剂、皮质类固醇和祛痰药）和外科手术方案（包括膀胱切除术、肺移植、肺减容术和瓣膜治疗）。这种二分法凸显了整合药物优化和治疗选择标准的协调护理路径的必要性。

美洲、欧洲、中东和非洲以及亚太地区在监管、报销和医疗保健服务方面的区域差异如何影响医疗服务取得和商业化策略？

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的临床实践、法律规范和商业策略都产生了重大影响。在美洲，对整合式医疗保健系统和基于价值的医疗模式的重视，使得能够显着减少住院次数并改善患者长期预后的治疗方法和干预措施成为优先事项，这促使支付方和医疗服务提供者仔细审查疗效比较和总医疗成本。这种环境推动了人们对长期维持疗法和支持用药依从性的医疗设备创新日益增长的兴趣。

为满足肺气肿治疗的多方面需求，推动药物治疗、医疗设备和手术解决方案发展的公司的竞争概况和策略挑战。

肺气肿治疗领域的竞争格局由众多参与者所构成，包括成熟的製药公司、专业的医疗设备製造商以及致力于研发创新治疗方法的生技公司。成熟公司凭藉其丰富的呼吸系统产品系列、与医疗专业人士的紧密联繫以及完善的分销网络，在医院和零售通路中保持着稳固的市场地位。同时，新参与企业则专注于差异化的作用机制、标靶的医疗设备与药物组合或手术创新，力求开闢临床与商业性上的利基市场。策略联盟和许可协议仍然至关重要，因为各公司都希望将临床专业知识与医疗设备工程相结合，并透过合作开发加速市场进入。

为产业领导者提供切实可行的策略建议，以协调临床证据、医疗设备创新、供应链韧性和进入本地市场。

产业领导者应制定一套切实可行的建议，以协调临床差异化、商业性可行性和营运韧性。首先，应优先创建整合证据，将随机对照试验数据与真实世界临床结果相结合，重点关注诸如减少病情加重、避免住院和提高生活品质等指标，以满足支付方和指南的要求。将这些临床数据转化为清晰的价值提案，既要考虑短期资源影响，又要兼顾长期健康效益。

采用以证据主导的调查方法，结合系统性文献回顾、对临床医生和管理人员的访谈以及供应链政策分析来检验研究结果。

本分析的调查方法结合了严谨的二手资料分析和有针对性的定性研究，以确保其具有全面且基于证据的观点。对同行评审的临床文献、监管指南和公共卫生指南的系统性回顾提供了其临床和科学背景。除此之外，本研究也透过评估医疗设备核准情况、手术相关文献和技术评估报告，捕捉了药物治疗和外科领域的进展。

一项权威的综合分析强调了临床创新、营运韧性和区域特定市场策略对于肺气肿治疗成功的关键作用。

总之，肺气肿治疗目前正处于一个转折点，药物疗效的提升、给药方式的创新以及手术技术的进步，与不断变化的支付方期望和区域差异交织在一起。临床决策越来越以对患者和医疗保健系统至关重要的结果为导向，相关人员也透过强调持续维持治疗、利用更先进的医疗设备提高遵守用药以及精准选择手术适应症来应对这一趋势。这些趋势为兼顾临床疗效、扩充性和经济合理性的差异化治疗策略创造了机会。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗方法分類的肺气肿治疗市场

  • 药物治疗
    • 抗生素
    • 支气管扩张剂
    • 皮质类固醇
    • 祛痰药
  • 外科
    • 切除术
    • 肺移植
    • 肺减容手术
    • 瓣膜治疗

第九章：肺气肿治疗市场：依药物类别划分

  • 抗胆碱能药物
  • β-激动剂
  • 组合药物

第十章：依治疗方法分類的肺气肿治疗市场

  • 辅助性治疗
  • 第一选择
  • 维持治疗
    • 联合治疗
    • 长效抗胆碱能药物
    • 长效β-激动剂
  • 急诊医学
    • 短效抗胆碱能药物
    • 短效β-激动剂

第十一章：肺气肿治疗市场：依给药途径划分

  • 吸入
    • 干粉吸入器
    • 定量吸入器
    • 喷雾器
    • 缓雾吸入器
  • 静脉
    • 静脉注射
    • 注射
  • 口服
    • 胶囊
    • 解决方案
    • 药片

第十二章：以剂型分類的肺气肿治疗市场

  • 胶囊
  • 吸入器
  • 喷雾器
  • 解决方案
  • 药片

第十三章：肺气肿治疗市场：依产品类型划分

  • 品牌商品
  • 非专利的

第十四章：肺气肿治疗市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十五章：肺气肿治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章：肺气肿治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 肺气肿治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国肺气肿治疗市场

第十九章 中国肺气肿治疗市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Chiesi Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols SA
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Olympus Corporation
  • Orion Corporation
  • Pfizer, Inc.
  • Pulmonx Corporation
  • ResMed, Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd
  • Theravance Biopharma, Inc.
  • Verona Pharma plc
  • Viatris Inc.
Product Code: MRR-1A1A064C021A

The Emphysema Treatment Market was valued at USD 7.32 billion in 2025 and is projected to grow to USD 7.84 billion in 2026, with a CAGR of 7.23%, reaching USD 11.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.32 billion
Estimated Year [2026] USD 7.84 billion
Forecast Year [2032] USD 11.94 billion
CAGR (%) 7.23%

A comprehensive introduction outlining the evolving emphysema treatment environment, clinical priorities, and emerging pressures shaping therapeutic decision-making

Emphysema remains a clinical and commercial priority within chronic respiratory disease management, driven by its progressive pathology, symptomatic burden, and high healthcare utilization. The therapeutic landscape comprises both pharmacological and surgical approaches, each carrying distinct clinical objectives: pharmacological strategies aim to control inflammation, relieve airflow obstruction, and reduce exacerbations, while surgical options are reserved for carefully selected patients to improve lung mechanics and quality of life. This introduction frames the converging forces reshaping patient care, innovation pipelines, and the payer environment.

Over recent years, clinical practice has shifted toward personalized treatment pathways that integrate long-acting bronchodilators, targeted anti-inflammatory regimens, and precision selection for surgical intervention. Advances in device technology and procedural techniques have refined therapeutic delivery, improving tolerability and adherence. At the same time, health systems are emphasizing value-based outcomes, prompting stakeholders to reevaluate treatment appropriateness, long-term management strategies, and interventions that meaningfully reduce hospital admissions.

Given these dynamics, industry participants-spanning drug developers, device manufacturers, payers, and provider networks-must reconcile clinical evidence with operational realities to design scalable solutions. This introduction sets the stage for a deeper exploration of how shifting scientific, regulatory, and economic pressures create both constraints and opportunities across the continuum of emphysema care.

How innovations in pharmacotherapy, device delivery, and procedural techniques are reshaping emphysema care pathways and stakeholder expectations

The landscape of emphysema treatment is undergoing transformative shifts driven by innovation in pharmacotherapy, refinement of surgical techniques, and a growing emphasis on integrated care models. Novel drug combinations and device platforms are expanding clinical options, while minimally invasive procedures and valve therapies provide alternatives for patients who historically had limited choices. These changes are not isolated; they interact with regulatory decisions, reimbursement pathways, and clinical guideline updates to accelerate adoption curves for certain interventions.

Concurrently, the shift toward patient-centered care has elevated metrics such as quality of life, exercise tolerance, and exacerbation reduction over simple physiological markers. This reorientation compels developers to demonstrate real-world effectiveness and durability of benefit. Advances in inhalation technologies, including dry powder and soft mist inhalers, are increasing the precision and convenience of drug delivery, thereby improving adherence and therapeutic effect. On the surgical side, refinements in lung volume reduction surgery and bronchoscopic valve therapy are generating new evidence for subgroup benefit, prompting multidisciplinary teams to reevaluate candidacy criteria.

These transformative shifts are amplified by digital health integration, remote monitoring, and telemedicine-enabled follow-up, which collectively support early intervention and tailored maintenance strategies. As stakeholders respond, the market is recalibrating toward interventions that can provide measurable patient benefit while aligning with payer expectations for cost-effectiveness and demonstrable outcomes.

Operational and strategic consequences of United States tariff realignments in 2025 on supply chains, procurement resilience, and clinical continuity for emphysema therapies

The cumulative impact of tariff and trade policy changes in the United States in 2025 created an operational context that healthcare manufacturers and distributors had to navigate carefully. Shifts in tariff schedules affected the importation costs of specialized inhalation devices, certain biopharmaceutical components, and surgical equipment used in advanced pulmonary procedures. Manufacturers responded by reassessing supply chains, renegotiating sourcing agreements, and accelerating localization of critical components to mitigate exposure to trade-related cost volatility.

These adjustments reverberated downstream, influencing procurement strategies for hospital systems and integrated care networks that procure a mix of pharmacological therapies and procedural devices. Some organizations shifted toward longer term contracting and regional supplier diversification to minimize disruptions. Regulatory and customs compliance requirements also increased administrative overhead, prompting stakeholders to invest in supply chain resilience and scenario planning.

Importantly, the policy environment catalyzed conversations about domestic manufacturing capacity and strategic inventory management for high-value components. The aggregate effect was a renewed focus on manufacturing agility and risk mitigation across the product lifecycle, with commercial teams integrating tariff sensitivity into pricing, contracting, and go-to-market planning to preserve access and maintain clinical continuity for patients reliant on complex emphysema treatments.

Multidimensional segmentation insights revealing how treatment type, drug class, therapy line, and delivery channels dictate clinical adoption and commercial positioning

Key segmentation insights illuminate how therapeutic choices and commercial pathways diverge across treatment type, drug class, therapy line, route of administration, dosage form, distribution channel, and product type. Based on treatment type, the market distinguishes pharmacological options-studied across antibiotics, bronchodilators, corticosteroids, and mucolytics-from surgical approaches that include bullectomy, lung transplantation, lung volume reduction surgery, and valve therapy; this dichotomy underscores the need for coordinated care pathways that integrate medication optimization with procedural selection criteria.

When considered through the lens of drug class, anticholinergics, beta-agonists, and combination drugs dominate clinical strategies for bronchodilation and symptom control, and their evolving formulations and delivery systems directly influence adherence and clinical outcomes. Therapy line segmentation-adjunctive, first-line, maintenance, and rescue-reveals how interventions are positioned across the patient journey; within maintenance strategies, combination therapy, long-acting anticholinergics, and long-acting beta-agonists are central to sustained disease control, while rescue options rely on short-acting anticholinergics and short-acting beta-agonists to address acute symptom flares.

Route of administration is a critical commercial and clinical differentiator: inhalation modalities such as dry powder inhaler, metered dose inhaler, nebulizer, and soft mist inhaler remain primary for chronic management, whereas intravenous approaches-infusion and injection-are typically reserved for acute care or hospital-based interventions, and oral formulations including capsule, solution, and tablet provide convenience for certain therapeutic classes. Dosage form segmentation across capsule, inhaler, nebulizer, solution, and tablet aligns closely with route considerations and patient adherence profiles. Distribution channel patterns-hospital pharmacy, online pharmacy, and retail pharmacy-reflect evolving purchasing behaviors and the increasing relevance of omnichannel access to therapies. Finally, product type segmentation between brand and generic options determines pricing dynamics, formulary placement, and uptake, particularly where generics enable broader access but branded innovations support premium positioning. Collectively, these segmentation lenses offer a multidimensional view that informs product development, commercial targeting, and clinical pathway design.

How regional regulatory, reimbursement, and healthcare delivery differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and commercialization strategies

Regional dynamics exert a strong influence on clinical practice, regulatory frameworks, and commercial strategy across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, emphasis on integrated health systems and value-based care models has prioritized therapies and interventions that demonstrably reduce hospitalizations and improve long-term patient outcomes, prompting payers and providers to scrutinize comparative effectiveness and total cost of care. This environment fuels interest in durable maintenance regimens and device innovations that support adherence.

Within Europe, Middle East & Africa, diverse regulatory pathways and heterogeneous healthcare funding mechanisms require tailored market access plans that account for country-specific reimbursement criteria and clinical guideline adoption. Stakeholders in this region often balance innovative therapeutics with local affordability considerations, creating opportunities for differentiated access strategies that pair clinical evidence with pragmatic pricing models. Across Asia-Pacific, rapid adoption of advanced inhalation technologies and growing investment in specialist pulmonary services are expanding the addressable patient population for both pharmacological and procedural interventions; however, variations in healthcare infrastructure and reimbursement across countries necessitate flexible commercialization approaches.

These regional distinctions underscore the importance of aligning clinical development and market access activities with localized evidence generation, stakeholder engagement, and distribution strategies. Companies that tailor their evidence packages, delivery modalities, and pricing structures to regional priorities are better positioned to achieve sustainable adoption and to scale interventions across multiple healthcare contexts.

Competitive profile and strategic imperatives for companies advancing pharmacological, device-based, and procedural solutions to address multifaceted emphysema care needs

Competitive dynamics in emphysema treatment are shaped by a mix of established pharmaceutical companies, specialized device manufacturers, and emerging biotech organizations pursuing novel therapeutic modalities. Incumbent players leverage broad respiratory portfolios, deep clinician relationships, and distribution networks to maintain access across hospitals and retail channels, while emerging entrants focus on differentiated mechanisms, targeted device-drug combinations, or procedural innovation to create clinical and commercial niches. Strategic partnerships and licensing agreements remain pivotal as companies aim to combine clinical expertise with device engineering or to accelerate market entry through co-development.

R&D intensity is concentrated on improving patient outcomes through longer-acting agents, combination formulations, and inhaler technologies that reduce systemic exposure and improve adherence. On the procedural side, device refinements and improved patient selection algorithms are expanding the candidate pool for lung volume reduction and valve therapies. Corporate strategy increasingly blends lifecycle management of legacy products with targeted investment in evidence generation to support label expansion or new guideline recommendations.

M&A and alliance activity gravitates toward capability gaps-such as inhalation device platforms or digital health solutions that enable remote monitoring and adherence support. Companies that can demonstrate integrated value propositions combining clinical efficacy, improved patient experience, and logistical simplicity stand to gain traction with payers and providers. Overall, competitive success hinges on evidence-driven differentiation, agile commercialization models, and close engagement with multidisciplinary clinical teams.

Actionable strategic recommendations for industry leaders to align clinical evidence, device innovation, supply chain resilience, and regional market access execution

Industry leaders should pursue a set of actionable recommendations that align clinical differentiation with commercial pragmatism and operational resilience. First, prioritize integrated evidence generation that pairs randomized controlled trial data with real-world outcomes, emphasizing measures such as exacerbation reduction, hospitalization avoidance, and quality of life improvements to meet payer and guideline expectations. Translate these clinical data into clear value narratives that address both short-term resource impact and long-term health benefits.

Second, invest in device and formulation optimization to enhance adherence and patient experience; innovations that simplify dosing, reduce handling complexity, or improve delivery efficiency can materially affect therapeutic efficacy in routine practice. Third, strengthen supply chain resilience by diversifying suppliers, localizing critical manufacturing capabilities where feasible, and incorporating tariff sensitivity into procurement and pricing models to reduce exposure to trade disruption. Fourth, tailor market access strategies to regional realities by developing country-specific evidence packages and adaptive pricing approaches that respect local reimbursement frameworks while preserving commercial viability.

Fifth, pursue strategic partnerships that combine clinical expertise, device engineering, and digital health capabilities to create bundled solutions that resonate with multidisciplinary care teams. Finally, embed patient-centricity across development and commercial activities by leveraging patient-reported outcomes, adherence analytics, and support programs that facilitate sustained engagement. These recommendations together support robust clinical uptake and sustainable commercial performance.

An evidence-driven research methodology blending systematic literature review, clinician and executive interviews, and supply chain policy analysis to validate insights

The research methodology underpinning this analysis combined rigorous secondary intelligence with targeted qualitative engagement to ensure a comprehensive, evidence-based perspective. A systematic review of peer-reviewed clinical literature, regulatory guidance, and public health directives provided the foundational clinical and scientific context. This review was complemented by an appraisal of device approvals, procedural technique literature, and technology assessment reports to capture advancements in both pharmacological and surgical domains.

To enrich the secondary evidence base, structured interviews were conducted with clinical specialists, procurement leaders, and industry executives to surface practical insights on treatment adoption, patient selection, and operational constraints. These qualitative engagements helped validate trends observed in the literature and clarified how reimbursement and delivery models influence real-world decision-making. The methodology also included an assessment of supply chain and policy developments, focusing on how tariff adjustments and trade policy changes affect manufacturing and distribution strategies.

Data synthesis emphasized triangulation across sources to reduce bias and to highlight convergent conclusions. Limitations were acknowledged where evidence gaps persist, and recommendations were framed to be actionable within the context of identified uncertainties. This methodological approach ensures that the conclusions are grounded in multifaceted evidence and validated practitioner perspectives.

A conclusive synthesis emphasizing how clinical innovation, operational resilience, and localized market strategies will determine success in emphysema treatment

In conclusion, the emphysema treatment landscape is at an inflection point where pharmacological refinements, delivery innovations, and procedural advances converge with evolving payer expectations and regional heterogeneity. Clinical decision-making is increasingly guided by outcomes that matter to patients and health systems, and stakeholders are responding by emphasizing durable maintenance regimens, improved adherence through better devices, and precise surgical selection. These dynamics create opportunities for differentiated therapeutic strategies that combine clinical effectiveness with scalability and economic rationale.

Operationally, trade policy shifts and supply chain pressures underscore the need for manufacturers and distributors to enhance resilience and to incorporate policy sensitivity into commercial planning. Region-specific approaches will be essential, as regulatory frameworks, reimbursement models, and healthcare delivery capacities vary substantially across markets. Competitive success will favor organizations that integrate robust evidence generation, strategic partnerships, and patient-centric product design.

Moving forward, decision-makers should adopt a balanced strategy that prioritizes clinical value, operational agility, and localized market access plans. By aligning innovation with pragmatic execution, stakeholders can improve patient outcomes while navigating the complex commercial and policy landscape that frames contemporary emphysema care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Emphysema Treatment Market, by Treatment Type

  • 8.1. Pharmacological
    • 8.1.1. Antibiotics
    • 8.1.2. Bronchodilators
    • 8.1.3. Corticosteroids
    • 8.1.4. Mucolytics
  • 8.2. Surgical
    • 8.2.1. Bullectomy
    • 8.2.2. Lung Transplantation
    • 8.2.3. Lung Volume Reduction Surgery
    • 8.2.4. Valve Therapy

9. Emphysema Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta-Agonists
  • 9.3. Combination Drugs

10. Emphysema Treatment Market, by Therapy Line

  • 10.1. Adjunctive
  • 10.2. First-Line
  • 10.3. Maintenance
    • 10.3.1. Combination Therapy
    • 10.3.2. Long-Acting Anticholinergics
    • 10.3.3. Long-Acting Beta-Agonists
  • 10.4. Rescue
    • 10.4.1. Short-Acting Anticholinergics
    • 10.4.2. Short-Acting Beta-Agonists

11. Emphysema Treatment Market, by Route Of Administration

  • 11.1. Inhalation
    • 11.1.1. Dry Powder Inhaler
    • 11.1.2. Metered Dose Inhaler
    • 11.1.3. Nebulizer
    • 11.1.4. Soft Mist Inhaler
  • 11.2. Intravenous
    • 11.2.1. Infusion
    • 11.2.2. Injection
  • 11.3. Oral
    • 11.3.1. Capsule
    • 11.3.2. Solution
    • 11.3.3. Tablet

12. Emphysema Treatment Market, by Dosage Form

  • 12.1. Capsule
  • 12.2. Inhaler
  • 12.3. Nebulizer
  • 12.4. Solution
  • 12.5. Tablet

13. Emphysema Treatment Market, by Product Type

  • 13.1. Brand
  • 13.2. Generic

14. Emphysema Treatment Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Emphysema Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Emphysema Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Emphysema Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Emphysema Treatment Market

19. China Emphysema Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Amgen Inc.
  • 20.6. Astellas Pharma Inc.
  • 20.7. AstraZeneca plc
  • 20.8. Baxter International Inc.
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Boston Scientific Corporation
  • 20.11. Chiesi Farmaceutici S.p.A.
  • 20.12. Cipla Limited
  • 20.13. GlaxoSmithKline plc
  • 20.14. Grifols S.A.
  • 20.15. Johnson & Johnson Services, Inc.
  • 20.16. Merck & Co., Inc.
  • 20.17. Mylan N.V.
  • 20.18. Novartis AG
  • 20.19. Olympus Corporation
  • 20.20. Orion Corporation
  • 20.21. Pfizer, Inc.
  • 20.22. Pulmonx Corporation
  • 20.23. ResMed, Inc.
  • 20.24. Roche Holding AG
  • 20.25. Sandoz International GmbH
  • 20.26. Sanofi S.A.
  • 20.27. Sunovion Pharmaceuticals Inc.
  • 20.28. Teva Pharmaceutical Industries Ltd
  • 20.29. Theravance Biopharma, Inc.
  • 20.30. Verona Pharma plc
  • 20.31. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EMPHYSEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EMPHYSEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MUCOLYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BULLECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY VALVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BETA-AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADJUNCTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DRY POWDER INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY METERED DOSE INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOFT MIST INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY NEBULIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 288. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 289. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 293. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 295. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 296. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 297. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 298. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GCC EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGICAL, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY MAINTENANCE, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY RESCUE, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS EMPHYSEMA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 330. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 331. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 333. G7 EMPHYSEMA TREATMENT MARKET SIZE, BY SURGI